Proven Expertise in Multiple Artery Living Donor Kidney Transplantation
About three percent of donor kidneys will have three or more arteries, and 13 percent of donor kidneys will have at least two arteries.
Adult Polycystic Kidney Disease with End Stage Renal Disease
Stephen Bartlett, M.D., The Peter Angelos Distinguished Professor and Chairman, Department of Surgery, University of Maryland School of Medicine, shares a lecture from a presentation at the Polycystic Kidney Foundation’s National Conference in Orlando, Fl
University of Maryland Expands Liver Transplantation Program to Pediatrics
With one of the most robust adult liver transplantation programs in the United States — and the largest organ transplant center in the tri-state area — University of Maryland Medical Center (UMMC) is now expanding these capabilities...
Si Pham, MD, cardiac surgeon and heart/lung transplant specialist, discusses how Ex Vivo Lung Perfusion helps to increase the donor pool for lung transplant recipients. Viewers can also see how Ex Vivo Lung Perfusion works.
Polycystic Kidney Disease Treatment
The University of Maryland Division of Transplantation is one of only a handful of centers in the country that will treat polycystic kidney disease by removing both dysfunctional kidneys and replacing it with a kidney from a living donor in one operation.
Laparoendoscopic Single Site (LESS) Donor Nephrectomy: Technique and Outcomes
University of Maryland researchers found that living donors whom donated a kidney that was removed through a single port in the navel report higher satisfaction in several key categories, compared to donors who underwent traditional multiple-port laparoscopic removal. The results were recently published in the Annals of Surgery.
Recellularization: The Future of Liver Transplantation
Patients with heart failure have heart pumps and ventricular assist devices that allow their hearts to keep beating.
UMMC at Forefront of Milestone Advances in Hepatitis C
With an urban population exhibiting numerous risk factors for the silent killer hepatitis C, University of Maryland specialists have taken aim at the surprisingly prevalent virus with leading-edge research and community programs — just as FDA approval has been granted for a stunningly advanced therapy that could skyrocket the condition’s cure rate.